Innovating the Pink Eye Treatment Landscape

Leading candidate in Phase 2B for the treatment of Acute Infectious Conjunctivitis.

Enhancing Lives Through Better Vision

Okogen is a clinical stage ophthalmic pharmaceutical company. Our lead product is in clinical trials as a “one stop shop” treatment for all forms of acute infectious conjunctivitis, including bacterial and viral.

Pink eye (conjunctivitis) is when the conjunctiva is irritated by a viral or bacterial infection or allergies. Bacterial and viral conjunctivitis are easily spread from person to person.

– American Academy of Ophthalmology

The current conjunctivitis market is USD $4.2 billion annually and is estimated to reach $6.1 billion by 2031.
85% of this market is driven by antibiotics that are prescribed regardless of etiology of infection
Infectious conjunctivitis represents ~60% of the total conjunctivitis market and 1-2% of all primary care visits worldwide
There are currently no approved treatments for adenoviral conjunctivitis, comprising +90% of all viral ocular infections
Okogen is pursuing a comprehensive treatment for both bacterial and viral conjunctivitis

Latest News & Press

View All News

Press Release

Okogen Announces Regulatory Submission to CDSCO for EMERALD STUDY and Appointment of New Chief Medical Officer

April 2, 2025

News

Around the Globe Webinar Series: Latest Developments and Innovations at Okogen, Inc.

April 1, 2025

Press Release

Okogen Inc. Secures $3.3M to Advance Phase 2b Clinical Program for Pink Eye (Acute Infectious Conjunctivitis)

December 11, 2024